Vetter Pharma International GmbH - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Vetter Development Service: Filling your clinical development needs

Vetter Development Service supports your drug-development projects, from inception to market launch. Our Chicago facility, along with our existing sites, provides clinical manufacturing from preclinical development through Phase II, with scale-up and transfer to our commercial manufacturing facilities.

Early planning can help save costs: Together, we work with you to develop the appropriate delivery system for your drug, starting in early development. In addition to matching all components to your product’s specifications, we replicate commercial manufacturing processes in our laboratories, which can prevent surprises when your drug reaches market production. Once products reach Phase III, we provide seamless transfer to our large-scale manufacturing facilities in Europe for late-stage and commercial production. Simultaneous activities, coupled with expertise and foresight, reduce time to market. To help prolong your success, Vetter also offers support on product lifecycle management, which ideally begins in the preclinical phase and becomes an integral part of the drug development process.

A leading manufacturer of aseptically prefilled drug-delivery systems, Vetter offers extensive experience with a broad array of substances, including monoclonal antibodies, peptides, interferons and vaccines.

Vetter Development Service provides:

  • Formulation support
  • Process development
  • Clinical trial manufacturing
  • Analytical service
  • Regulatory support

Website: www.vetter-pharma.com
E-mail: info@vetter-pharma.com

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
FindPharma Custom Search

Click here